Quote:
|
Conclusion: Given the difference in baseline risk and severity levels across studies, ARR is the appropriate way to compare DMDs in the absence of head-to-head clinical trials. Results based on ARR showed that IFNB-1a sc has comparable therapeutic effect on efficacy measures when compared to natalizumab.
|
I'm sure when the insurance companies' docs read this kind of report, they aren't exactly going to be eager in recommending that Tysabri be covered without a lot of red tape.
Harry